[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608956":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":7,"responsibleParty":20,"collaborators":7,"id":22,"slug":7,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":26,"eligibilityCriteria":27,"healthyVolunteers":23,"sex":28,"minAge":29,"maxAge":7,"enrollmentInfo":30,"targetDuration":33,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Shanghai Pudong New Area Gongli Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Mierxiati Abudurexiti","STUDY_CHAIR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Mierxiati Abudurexiti, MD. PhD.","CONTACT","18939915308","mierxiati@fudan.edu.cn",{"name":10,"role":15,"phone":19,"phoneExt":7,"email":17},"+8618939915308",{"type":21,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100608956",false,"NCT07208292","Real-world Study on Preoperative Application of Rezvilutamide","RWS-GU001","Inclusion Criteria:\n\n* Pathological confirmation: Confirmed as prostate adenocarcinoma by ultrasound\u002FMRI-guided prostate biopsy, with ISUP grade ≥ 2 (Gleason score ≥ 7);\n* Clinical staging (based on AJCC 8th edition):High-risk localized: cT3a or PSA \\> 20 ng\u002Fml or Gleason score ≥ 8;Locally advanced: cT3b-4 or positive pelvic lymph nodes (cN1);\n* Surgical feasibility: Multidisciplinary team (MDT) assessment considers that R0\u002FR1 resection can be achieved;\n* Laboratory requirements:Hemoglobin ≥ 90 g\u002FL, platelets ≥ 100×10\\^9\u002FL;Liver function: ALT\u002FAST ≤ 2.5×ULN, bilirubin ≤ 1.5×ULN;Renal function: eGFR ≥ 30 mL\u002Fmin\u002F1.73m².\n\nExclusion Criteria:\n\n* Disease-related: Distant metastasis (M1, including bone metastasis or visceral metastasis);Pathology indicating neuroendocrine differentiation or small cell carcinoma component \\> 10%;\n* Treatment-related:Previous history of receiving radiotherapy, cryotherapy, or systemic chemotherapy for prostate cancer;History of other malignant tumors within 5 years (except non-melanoma skin cancer);\n* Comorbidities: Uncontrolled cardiovascular diseases (e.g., NYHA Class III heart failure, myocardial infarction within 6 months);History of severe epilepsy (requiring long-term use of anticonvulsant drugs);・Others:Known allergy to relugolix or LHRH analogs;Participation in other interventional clinical trials.","MALE","18 Years",{"count":31,"type":32},115,"ESTIMATED","1 Year","OBSERVATIONAL","Real-world study on Preoperative Application of Rezvilutamide",[37],"Preoperative Evaluation",[39],"prostate cancer","NOT_YET_RECRUITING","2025-09-26",{"date":43,"type":44},"2025-10-06","ACTUAL",{"date":46,"type":32},"2025-10-15",{"date":48,"type":32},"2027-07-15",{"name":5,"class":6}]